1.Risk factors for kidney stones in patients with primary hyperparathyroidism
Shulei WANG ; An SONG ; Ou WANG ; Xiaoping XING
Chinese Journal of Endocrine Surgery 2025;19(1):120-123
Patients with primary hyperparathyroidism (PHPT) have an increased risk of kidney stones. Parathyroidectomy (PTX) is the main treatment for PHPT. However, the effect of PTX on kidney stones in patients with PHPT is unclear. This article summarizes the risk factors for kidney stones after PTX or not and the influence of PTX on the occurrence and development of renal stones in patients with PHPT, in order to explore the causes and mechanisms of PHPT and its postoperative renal stones.
2.Progress in mechanism and clinical application of miRNA regulating os-teogenesis-angiogenesis coupling in SONFH
Haiyuan GAO ; Mingwang ZHOU ; Xiaoping WANG ; Xing YANG ; Zhenhua SHI
Chinese Journal of Pathophysiology 2025;41(10):2030-2037
Steroid-induced osteonecrosis of the femoral head(SNOFH)is a prevalent challenging condition in orthopedics,characterized by a high disability rate and intricate pathophysiological mechanisms including diminished an-giogenesis and impaired osteogenic function.The concept of osteogenesis-angiogenesis coupling involves the interplay be-tween osteoblasts and angiogenesis.Restoring the blood supply to bone tissue,boosting bone cell activity,and facilitating bone regeneration are crucial for the recovery of SNOFH patients.Research has demonstrated the significant role of mi-croRNAs(miRNAs)in the coordination of osteogenesis and angiogenesis.MiRNAs have the ability to concurrently regu-late multiple target genes and signaling pathways associated with osteogenesis and angiogenesis,effectively stimulating the regeneration of bones and blood vessels.By considering the interaction of multiple miRNAs and their target genes,the de-velopment of a multi-target combination therapy approach could greatly enhance the treatment outcomes for SNOFH.Through a thorough investigation of miRNA interactions in the regulation of osteogenesis and angiogenesis,the progression of the disease can be elucidated,offering a fundamental basis for early diagnosis,precise treatment,and prognosis evalua-tion of SNOFH.This paper aims to uncover the pivotal nodes and regulatory connections in SNOFH by summarizing the in-volvement of miRNAs in the coupling of osteogenesis and angiogenesis.By identifying potential therapeutic targets and un-derstanding the coordinated function of miRNAs in osteogenesis and angiogenesis coupling,valuable insights can be gained for the personalized treatment of SNOFH.
3.Risk factors for kidney stones in patients with primary hyperparathyroidism
Shulei WANG ; An SONG ; Ou WANG ; Xiaoping XING
Chinese Journal of Endocrine Surgery 2025;19(1):120-123
Patients with primary hyperparathyroidism (PHPT) have an increased risk of kidney stones. Parathyroidectomy (PTX) is the main treatment for PHPT. However, the effect of PTX on kidney stones in patients with PHPT is unclear. This article summarizes the risk factors for kidney stones after PTX or not and the influence of PTX on the occurrence and development of renal stones in patients with PHPT, in order to explore the causes and mechanisms of PHPT and its postoperative renal stones.
4.Guideline for Adult Weight Management in China
Weiqing WANG ; Qin WAN ; Jianhua MA ; Guang WANG ; Yufan WANG ; Guixia WANG ; Yongquan SHI ; Tingjun YE ; Xiaoguang SHI ; Jian KUANG ; Bo FENG ; Xiuyan FENG ; Guang NING ; Yiming MU ; Hongyu KUANG ; Xiaoping XING ; Chunli PIAO ; Xingbo CHENG ; Zhifeng CHENG ; Yufang BI ; Yan BI ; Wenshan LYU ; Dalong ZHU ; Cuiyan ZHU ; Wei ZHU ; Fei HUA ; Fei XIANG ; Shuang YAN ; Zilin SUN ; Yadong SUN ; Liqin SUN ; Luying SUN ; Li YAN ; Yanbing LI ; Hong LI ; Shu LI ; Ling LI ; Yiming LI ; Chenzhong LI ; Hua YANG ; Jinkui YANG ; Ling YANG ; Ying YANG ; Tao YANG ; Xiao YANG ; Xinhua XIAO ; Dan WU ; Jinsong KUANG ; Lanjie HE ; Wei GU ; Jie SHEN ; Yongfeng SONG ; Qiao ZHANG ; Hong ZHANG ; Yuwei ZHANG ; Junqing ZHANG ; Xianfeng ZHANG ; Miao ZHANG ; Yifei ZHANG ; Yingli LU ; Hong CHEN ; Li CHEN ; Bing CHEN ; Shihong CHEN ; Guiyan CHEN ; Haibing CHEN ; Lei CHEN ; Yanyan CHEN ; Genben CHEN ; Yikun ZHOU ; Xianghai ZHOU ; Qiang ZHOU ; Jiaqiang ZHOU ; Hongting ZHENG ; Zhongyan SHAN ; Jiajun ZHAO ; Dong ZHAO ; Ji HU ; Jiang HU ; Xinguo HOU ; Bimin SHI ; Tianpei HONG ; Mingxia YUAN ; Weibo XIA ; Xuejiang GU ; Yong XU ; Shuguang PANG ; Tianshu GAO ; Zuhua GAO ; Xiaohui GUO ; Hongyi CAO ; Mingfeng CAO ; Xiaopei CAO ; Jing MA ; Bin LU ; Zhen LIANG ; Jun LIANG ; Min LONG ; Yongde PENG ; Jin LU ; Hongyun LU ; Yan LU ; Chunping ZENG ; Binhong WEN ; Xueyong LOU ; Qingbo GUAN ; Lin LIAO ; Xin LIAO ; Ping XIONG ; Yaoming XUE
Chinese Journal of Endocrinology and Metabolism 2025;41(11):891-907
Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.
5.Effectiveness and safety of zoledronate in the treatment of 24 Chinese patients with Paget disease of bone
An SONG ; Jing LIU ; Jiajia WANG ; Yingyu CHEN ; Yan JIANG ; Mei LI ; Weibo XIA ; Ou WANG ; Xiaoping XING ; Xunwu MENG
Chinese Journal of Endocrinology and Metabolism 2025;41(3):226-232
Objective:To evaluate the effectiveness and safety of zoledronic acid in patients with Paget′s disease of bone based on clinical data from a single medical center.Methods:This retrospective study included 24 patients diagnosed with Paget′s disease of bone and treated with zoledronic acid at Peking Union Medical College Hospital between January 2009 and June 2020. Demographic data, clinical symptoms, treatment efficacy, and safety outcomes were collected. The primary efficacy measure was serum alkaline phosphatase(ALP) levels. Treatment was considered effective if ALP levels returned to normal or decreased by more than 75% from baseline in the difference between the ALP level and its normal median value.Results:Among the 24 patients with Paget′s bone disease, the most commonly affected site was the skull(in 17 cases). All patients received a single 5 mg intravenous infusion of zoledronic acid. Serum ALP levels significantly decreased after treatment. Among the 15 patients who completed at least 3 months of follow-up, all achieved treatment success. The median time for serum ALP levels to reach the target was 13.1(9.4, 26.1) weeks. In 12 patients, ALP levels normalized within a medium of 16.9(11.5, 37.3) weeks, and remained stable over a medium follow-up of 4.56(2.42, 5.71) years. The most common side effects were hypocalcemia(21 cases, 87.5%) and flu-like symptoms(17 cases, 70.8%). Seven patients had severe hypocalcemia(serum calcium<1.75 mmol/L), and they had higher baseline levels of ALP, calcium, and phosphorus compared to those with mild hypocalcemia.Conclusions:Zoledronic acid 5 mg intravenous infusion effectively controlled disease activity in patients with Paget′s disease of bone. Generally, Most patients achieved treatment goals within 3-4 months, with sustained remission for a median of 4 years. Hypocalcemia was the most frequent side effect, underscoring the importance of timely calcium and vitamin D supplementation.
6.Progress of research on mechanisms and clinical applications of novel antibacterial materials in treating infectious bone defect
Xing YANG ; Mingwang ZHOU ; Xiaoping WANG ; Haiyuan GAO ; Xinhao LI
Chinese Journal of Nosocomiology 2025;35(19):3031-3035
Infectious bone defect,one of the complex and refractory types of bone defects,is characterized by infec-tion,inflammation and subsequent bone tissue destruction.These conditions often lead to severe consequences such as limb necrosis,dysfunction or even amputation.The previous treatment method for infectious bone defect primarily involves thorough debridement and bone grafting after infection control with antibacterial drugs.Howev-er,this method carries drawbacks,including the possibility of drug resistance and systemic toxicity due to high-dose use of antimicrobial drugs.With advancements in modern medicine and in-depth research on biomaterials,va-rious novel antibacterial materials have been increasingly applied in the treatment of infectious bone defect,demon-strating promising outcomes.This paper reviews the applications and therapeutic efficacy of novel antibacterial ma-terials in treating infectious bone defect at home and abroad,aiming to provide references for clinical management.
7.Focus on schistosomiasis cirrhosis: disease burden, pathogenic characteristics, and research frontiers
Xing HE ; Jianping ZHAO ; Qian CHEN ; Chuan SU ; Xiaoping CHEN
Chinese Journal of Hepatology 2025;33(5):412-415
Schistosomiasis cirrhosis (SAC), as the core pathological outcome of late-stage schistosomiasis, is an important challenge to global public health. Notably, there is still a significant disease burden, especially in the traditional endemic areas, such as the Yangtze River Basin in China. SAC has unique pathogenic characteristics, including insect-derived molecular-driven disease, chronic inflammation dominated by Th2 immunity, delayed pathogenicity, noticeable symptoms of portal hypertension, and an absence of significant correlation with liver cancer. Therefore, future research should focus on the determinants of individual susceptibility to SAC onset, the core mechanism of liver lesion progression post-pathogen clearance, time nodes, and intervention methods. Additionally, finding the high-risk individuals, analyzing of pathological mechanisms, and optimizing intervention strategies will help in promoting the development of clinical prevention and control and translational research.
8.Impact of an emotion management course on emotion regulation, coping strategies, and mental health among first-year university students
Yating NIU ; Ming QIAN ; Jinping ZHOU ; Qin YUAN ; Xiaoping XING
Shanghai Journal of Preventive Medicine 2025;37(3):265-270
ObjectiveTo develop an emotion management course and evaluate its effectiveness in improving emotion regulation, coping strategies, and anxiety and depression among first-year university students, so as to provide a basis for colleges to optimize mental health education courses. MethodsUsing a multi-stage cluster random sampling method, five classes of first-year students (n=169) from a university were randomly selected as participants, with three classes assigned to the experimental group (n=102) and two classes to the control group (n=67). The experimental group attended both the standard mental health education course and the emotion management course developed in this study, while the control group only attended the standard mental health education course. Pre- and post-intervention assessments were conducted using the Emotion Regulation Questionnaire (ERQ), Simplified Coping Style Questionnaire (SCSQ), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS). ResultsBefore the intervention, there were no significant differences between the experimental group and the control group in ERQ, SCSQ, SDS, and SAS scores (P>0.05). After the intervention, the experimental group demonstrated greater improvements than the control group in the ERQ expression inhibition subscale (14.42±5.05, 16.12±5.65), SCSQ positive coping tendency (1.97±0.51, 1.80±0.49) and negative coping tendency (1.26±0.55, 1.47±0.50), as well as in SDS (50.26±11.48, 53.86±8.21) and SAS (43.96±11.97, 47.59±9.50) scores (t value: 2.039, 2.144, 2.572; Z value: -2.214, -2.486; P<0.05). Compared with pre-intervention scores, the experimental group also showed improvements in the ERQ cognitive reappraisal subscale (32.19±5.76, 30.92±6.18), SCSQ positive coping tendency (1.97±0.51, 1.83±0.48), and SDS scores (50.26±11.48, 50.75±11.59) (t value: -2.654, -3.027; Z value: -2.100, P<0.05). ConclusionThe emotion management course effectively enhances students’ use of cognitive reappraisal strategies while reducing reliance on expressive suppression. It also contributes to improvements in coping strategies for life events and alleviates symptoms of depression and anxiety. Universities should consider integrating emotion management education into their curricula to enhance the mental well-being of first-year students.
9.Genetic and Clinical Characteristics of Pediatric Primary Hyperparathyroidism
Yingyu CHEN ; Ou WANG ; Xiaoping XING
Medical Journal of Peking Union Medical College Hospital 2025;16(6):1534-1540
Primary hyperparathyroidism(PHPT) is relatively rare in individuals before adulthood. Among juvenile patients, hereditary PHPT accounts for a significant proportion. Specifically, infant and toddler patients often carry gene mutations related to the calcium-sensing receptor signaling pathway, whereas children and adolescent patients predominantly exhibit mutations in genes associated with cell proliferation. Notably, PHPT in infants, children, and adolescents differs significantly from that in adult patients in terms of genetic background, clinical manifestations, treatment strategies, and prognosis. This article aims to systematically summarize the genetic characteristics and clinical features of juvenile-onset PHPT to enhance the physicians' understanding of this disease.
10.Two novel rare variants in the PTH gene found in patients with hypoparathyroidism
Yue JIANG ; An SONG ; Jiajia WANG ; Xinqi CHENG ; Jing YANG ; Yan JIANG ; Mei LI ; Weibo XIA ; Xiaoping XING ; Min NIE ; Ou WANG
Osteoporosis and Sarcopenia 2025;11(1):22-28
Objectives:
Hypoparathyroidism (HP) is a rare endocrine disorder caused by parathyroid hormone (PTH) defi ciency. The PTH is a candidate gene for familial isolated hypoparathyroidism (FIH). This study aimed to investigate the pathogenicity of two novel rare variants (RVs) ofPTH through in vitro functional study.
Methods:
Targeted next-generation sequencing was used to identify candidate gene mutations. Clinical data were retrospectively collected. Wild-type (WT) PTH was used as a template for site-directed mutagenesis to create mutant eukaryotic expression plasmids, which were transfected into cells. Treated with or without 4-phenylbu tyric acid (4-PBA), the levels of intact PTH (iPTH) and PTH (1-84) were measured by chemiluminescence, and protein expression was assessed using Western blotting.
Results:
Two patients carrying PTH mutations (c.154G > A: p.Val52Ile, c.270G > T: p.Leu90Phe) were identified.Patient 1, a 45-year-old male, presented with carpal and pedal numbness, muscle cramps, and low serum calcium (1.29 mmol/L). Patient 2, a 12-year-old female, had muscle twitches, convulsions, low calcium (1.50 mmol/L), and iPTH of 4 pg/mL. The iPTH or PTH (1-84) levels in the medium transfected with mutant Val52Ile and Leu90Phe PTH decreased by 31%–38%, and 51%–96% compared to WT (allP < 0.05), which were not rescued by 4-PBA. No significant changes in intracellular PTH expression were observed.
Conclusions
In this study, two novel RVs of PTH(Val52Ile and Leu90Phe) were identified that may impair hormone synthesis and secretion. Our study has broadened the mutation spectrum of the PTH and shed light on potential mechanisms underlying FIH.

Result Analysis
Print
Save
E-mail